Certis Oncology Solutions, Inc
The purpose of this observational study is to evaluate the clinical utility of investigational patient-derived cancer models, to assess the performance of biomarker-based therapeutic predictions in the patient-derived models. Each participant in the observational study will have a piece of cancer removed as part of routine, physician direct care and grown in laboratory mice, where multiple anti-cancer drugs can be tested on it simultaneously. Additional data will be provided to the oncologist; interpretation of the results and any clinical actions are at the sole discretion of the oncologist.
Participants are planned to undergo a procedure, such as a biopsy or surgery, as part of routine care. After enough tissue to complete all routine tests required for the participants' care are provided, if the participant decides to take part in this study, any leftover biopsy or surgically obtained tissue/fluid, and blood specimens will be sent to the Certis laboratory for testing. It will be required to provide details regarding the participants' biopsy, such as the date, location, and contact information for the study team performing the procedure. The oncologist will assist with this, and…
Inclusion Criteria: * Solid tumor patients stage 2-4. * Cancer patients who have been previously treated or shown resistance or refraction to standard-of-care therapies and where the implicated tissue has not been irradiated in the ten (10) weeks prior to excision. * Patients with tumors are amenable to biopsy or surgery for fresh tissue and blood procurement as part of routine clinical care * Patients must be referred by a healthcare professional * Willingness for tissue samples used in future research * Signed informed consent * Willingness to share diagnosis, available genetic/molecular pr…
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.